Trial Profile
A Prospective Observational Study to Evaluate the Relationship between Quality of Life and Disease State in Ankylosing Spondylitis Patients treated with Remicade (infliximab) or Simponi (golimumab)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2018
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Infliximab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms QUO-VADIS
- Sponsors Merck & Co
- 19 Jul 2018 Results published in the Clinical and Experimental Rheumatology
- 13 Mar 2013 New trial record